Elevation Oncology, Inc. announced on December 5, 2024, new preclinical data demonstrating the combination potential of EO-3021, a Claudin 18.2 antibody-drug conjugate (ADC). The data, presented at the ESMO Immuno-Oncology Annual Congress 2024, showed synergistic anti-tumor activity when EO-3021 was combined with VEGFR2 or PD-1 inhibitors.
The preclinical studies indicated enhanced anti-tumor activity for both combination regimens, supporting the company's planned clinical strategy. Elevation Oncology expects to initiate dosing in the combination portion of its ongoing Phase 1 clinical trial of EO-3021 in the fourth quarter of 2024.
These combination cohorts will evaluate EO-3021 with ramucirumab, a VEGFR2 inhibitor, and dostarlimab, a PD-1 inhibitor, in patients with gastric/GEJ cancer. This builds on initial monotherapy data from August 2024, which demonstrated an objective response rate of 42.8% in a biomarker-enriched patient population.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.